Clinical trials: ALL, Adult, open to volunteers
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.
- Conditions
- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
- Trial name
- NCT03628612
- Testing
- AUTO CAR T cell therapy
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 500 people
- Sponsor
- Autolus Limited
Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.
- Trial name
- NCT07312630
- Testing
- LV009 Injection Infusion
- Where
- China
- Volunteers
- 19 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
T-ALL/Lymphoma
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD5 CAR-NK in the treatment of patients with relapsed/refractory T-Cell hematologic malignancies.
- Trial name
- NCT06909474
- Testing
- Anti-CD5 CAR NK cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd